HLB Pharmaceutical Co. Ltd (047920) - Total Liabilities

Latest as of September 2025: ₩46.98 Billion KRW ≈ $31.84 Million USD

Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has total liabilities worth ₩46.98 Billion KRW (≈ $31.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore HLB Pharmaceutical Co. Ltd (047920) net asset momentum to track the company's year-over-year net asset growth rate.

HLB Pharmaceutical Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how HLB Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See HLB Pharmaceutical Co. Ltd (047920) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

HLB Pharmaceutical Co. Ltd Competitors by Total Liabilities

The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Mediwound Ltd
NASDAQ:MDWD
USA $34.98 Million
XINTE ENERGY CO. CL.H YC1
F:9M7
Germany €45.07 Billion
Shangri La Hotels Malaysia Bhd
KLSE:5517
Malaysia RM385.77 Million
Aurum PropTech Limited
NSE:AURUM
India Rs4.14 Billion
GoldMining Inc
TO:GOLD
Canada CA$10.07 Million
SCH Group Bhd
KLSE:0161
Malaysia RM626.22 Million
Tarsons Products Limited
NSE:TARSONS
India Rs5.37 Billion
P2 Gold Inc
V:PGLD
Canada CA$1.44 Million

Liability Composition Analysis (2014–2024)

This chart breaks down HLB Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 047920 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.95 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HLB Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HLB Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual total liabilities of HLB Pharmaceutical Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩41.53 Billion
≈ $28.15 Million
-21.93%
2023-12-31 ₩53.20 Billion
≈ $36.05 Million
-5.42%
2022-12-31 ₩56.25 Billion
≈ $38.12 Million
+14.22%
2021-12-31 ₩49.25 Billion
≈ $33.37 Million
-26.27%
2020-12-31 ₩66.80 Billion
≈ $45.27 Million
+130.06%
2019-12-31 ₩29.04 Billion
≈ $19.68 Million
+49.48%
2018-12-31 ₩19.42 Billion
≈ $13.16 Million
-15.71%
2017-12-31 ₩23.04 Billion
≈ $15.62 Million
+3.16%
2016-12-31 ₩22.34 Billion
≈ $15.14 Million
+76.31%
2015-12-31 ₩12.67 Billion
≈ $8.59 Million
-23.77%
2014-12-31 ₩16.62 Billion
≈ $11.26 Million
--

About HLB Pharmaceutical Co. Ltd

KQ:047920 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$181.15 Million
₩267.31 Billion KRW
Market Cap Rank
#16857 Global
#621 in Korea
Share Price
₩8150.00
Change (1 day)
+2.77%
52-Week Range
₩6170.00 - ₩20900.00
All Time High
₩41100.00
About

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more